Identifying advanced MAFLD in a cohort of T2DM and clinical features
BackgroundMAFLD is the most common cause of chronic liver disease, affecting 25% of the global population. Patients with T2DM have an increased risk of developing MAFLD. In addition, patients with T2DM have a higher risk of advanced forms of steatohepatitis and fibrosis. Identifying those patients i...
Main Authors: | Ana Maria Sanchez-Bao, Alfonso Soto-Gonzalez, Manuel Delgado-Blanco, Vanesa Balboa-Barreiro, Diego Bellido |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1058995/full |
Similar Items
-
From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
by: Alexandra Gatzios, et al.
Published: (2022-01-01) -
From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
by: Andrea Boccatonda, et al.
Published: (2023-03-01) -
MAFLD: How is it different from NAFLD?
by: Cameron Gofton, et al.
Published: (2023-02-01) -
The NAFLD–MAFLD debate through the lens of the Arab world
by: Mina Tharwat, et al.
Published: (2022-01-01) -
Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease
by: Patrice Marques, et al.
Published: (2023-01-01)